Haematology and Iron Overload
Pharmacosmos A/S supports clinical research in transfusion-dependent thalassemia, low-risk myelodysplastic syndromes, and related iron overload conditions, with interest in therapies that address chronic transfusion burden and iron accumulation.
- α- and β-thalassemia
- Myelodysplastic syndromes
- Iron chelation
The sponsor’s research activity also extends to agents intended for iron removal and management of haemolysis in transfusion-related disorders.
Cardiology
Clinical trials include work in chronic heart failure with a focus on iron deficiency and its relationship to cardiovascular outcomes, including hospitalisation risk and cardiovascular mortality.
- Symptomatic chronic heart failure
- Intravenous iron therapy
- Iron-deficient patients
This area reflects interest in correcting iron deficiency as part of supportive treatment in patients with persistent cardiac symptoms.
Oncology
Pharmacosmos A/S is involved in research for extensive-stage small cell lung cancer, with attention to treatment settings that combine anticancer therapy with supportive measures during chemotherapy.
- Small cell lung cancer
- Supportive oncology
- Chemotherapy-associated care
The oncology portfolio shows interest in maintaining treatment tolerance and clinical outcomes in aggressive lung cancer care.
Iron Metabolism and Pharmacology
Additional research activity includes studies in healthy volunteers examining how candidate medicines are processed in the body, indicating interest in drug absorption, distribution, and elimination for iron-related compounds.
- Pharmacokinetics
- Oral and injectable formulations
- Iron-based therapeutics
This work aligns with the sponsor’s broader focus on medicines for iron homeostasis and disorders linked to abnormal iron handling.
